1176 related articles for article (PubMed ID: 8546987)
1. Enhancement of the depigmenting effect of hydroquinone by cystamine and buthionine sulfoximine.
Bolognia JL; Sodi SA; Osber MP; Pawelek JM
Br J Dermatol; 1995 Sep; 133(3):349-57. PubMed ID: 8546987
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the depigmenting effect of hydroquinone and 4-hydroxyanisole by all-trans-retinoic acid (tretinoin): the impairment of glutathione-dependent cytoprotection?
Kasraee B; Handjani F; Aslani FS
Dermatology; 2003; 206(4):289-91. PubMed ID: 12771467
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
4. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
Prezioso JA; FitzGerald GB; Wick MM
J Invest Dermatol; 1992 Sep; 99(3):289-93. PubMed ID: 1512464
[TBL] [Abstract][Full Text] [Related]
5. Promotion of trans-platinum in vivo effects on renal heme and hemoprotein metabolism by D,L-buthionine-S,R-sulfoximine. Possible role of glutathione.
Mayer RD; Maines MD
Biochem Pharmacol; 1990 May; 39(10):1565-71. PubMed ID: 2337413
[TBL] [Abstract][Full Text] [Related]
6. Characterization of quinone reductase, glutathione and glutathione S-transferase in human myeloid cell lines: induction by 1,2-dithiole-3-thione and effects on hydroquinone-induced cytotoxicity.
Li Y; Lafuente A; Trush MA
Life Sci; 1994; 54(13):901-16. PubMed ID: 7511200
[TBL] [Abstract][Full Text] [Related]
7. Glutathione depletion increases tyrosinase activity in human melanoma cells.
del Marmol V; Solano F; Sels A; Huez G; Libert A; Lejeune F; Ghanem G
J Invest Dermatol; 1993 Dec; 101(6):871-4. PubMed ID: 7902381
[TBL] [Abstract][Full Text] [Related]
8. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo.
Révész L; Edgren MR; Wainson AA
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):403-6. PubMed ID: 8195041
[TBL] [Abstract][Full Text] [Related]
9. Mechanism(s) regulating inhibition of thymidylate synthase and growth by gamma-L-glutaminyl-4-hydroxy-3-iodobenzene, a novel melanin precursor, in melanogenic melanoma cells.
Prezioso JA; Damodaran KM; Wang N; Bloomer WD
Biochem Pharmacol; 1993 Jan; 45(2):473-81. PubMed ID: 8435097
[TBL] [Abstract][Full Text] [Related]
10. Enzyme induction by L-buthionine (S,R)-sulfoximine in cultured mouse hepatoma cells.
Shertzer HG; Vasiliou V; Liu RM; Tabor MW; Nebert DW
Chem Res Toxicol; 1995; 8(3):431-6. PubMed ID: 7578930
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
Kable EP; Favier D; Parsons PG
Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
[TBL] [Abstract][Full Text] [Related]
12. Purification and characterization of gamma-glutamylcysteine synthetase from Ascaris suum.
Hussein AS; Walter RD
Mol Biochem Parasitol; 1995 Jun; 72(1-2):57-64. PubMed ID: 8538700
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
14. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
Shrieve DC; Denekamp J; Minchinton AI
Radiat Res; 1985 Jun; 102(3):283-94. PubMed ID: 4070545
[TBL] [Abstract][Full Text] [Related]
15. Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.
Prezioso JA; Fitzgerald GB; Wick MM
Pigment Cell Res; 1990; 3(2):49-54. PubMed ID: 2117268
[TBL] [Abstract][Full Text] [Related]
16. Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice.
Ford JM; Yang JM; Hait WN
Cancer Res; 1991 Jan; 51(1):67-72. PubMed ID: 1988108
[TBL] [Abstract][Full Text] [Related]
17. Depigmenting action of hydroquinone depends on disruption of fundamental cell processes.
Penney KB; Smith CJ; Allen JC
J Invest Dermatol; 1984 Apr; 82(4):308-10. PubMed ID: 6200545
[TBL] [Abstract][Full Text] [Related]
18. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
19. Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell sensitization.
Mizutani Y; Yoshida O
Cancer; 1994 Feb; 73(3):730-7. PubMed ID: 8299097
[TBL] [Abstract][Full Text] [Related]
20. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency.
Boissy RE; Visscher M; DeLong MA
Exp Dermatol; 2005 Aug; 14(8):601-8. PubMed ID: 16026582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
